Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
BeOne Medicines
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06585488CT.gov A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Esophageal Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Bgb-53038 (this asset) | BeOne Medicines | P1 | CC · 43 |
| Cetuximab | BeOne Medicines | P2 | B |
| Capecitabine | I-Mab Biopharma US Limited | P3 | B |
| Tislelizumab | BeOne Medicines | P3 | B |
| Oxaliplatin | I-Mab Biopharma US Limited | P3 | B |
| Fluorouracilum | I-Mab Biopharma US Limited | P3 | B |
| Durvalumab | University of California, Irvine | P2 | B |
| Cis-Diamminedichloroplatinum Ii | Taiho Oncology, Inc. | P3 | B |
| Pembrolizumab | Diwakar Davar | P3 | B |
+42 more in the Esophageal Adenocarcinoma cohort
Other indications for Bgb-53038
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P1 | CC · 43 |
| Gastric Cancer | — | P1 | CC · 43 |
| Gastroesophageal Junction Adenocarcinoma | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Bgb-53038 in Esophageal Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/bgb-53038-esophageal-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →